Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669686 | 0.88 | FTO (0.45) | ABCB1ABCC1CYP11B2CYP11B1 | |
| SCHEMBL32669844 | 0.83 | FTO (0.47) | ABCB1ABCC1CYP11B2CYP11B1ERN1 | |
| SCHEMBL32669508 | 0.83 | FTO (0.52) | ABCB1ABCC1CYP11B2CYP11B1 | |
| SCHEMBL32669519 | 0.81 | FTO (0.44) | ABCB1ABCC1CYP11B2CYP11B1 | |
| SCHEMBL32669943 | 0.81 | COMT (0.35) | — | |
| SCHEMBL32670035 | 0.80 | FTO (0.47) | ABCB1ABCC1CYP11B2CYP11B1 | |
| SCHEMBL32669700 | 0.80 | COMT (0.42) | ABCB1ABCC1CYP11B2CYP11B1 | |
| SCHEMBL32669922 | 0.79 | MEN1 (0.38) | — | |
| SCHEMBL32669874 | 0.79 | MAPK14 (0.33) | — | |
| SCHEMBL32669936 | 0.79 | S1PR3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | ABCB1 1475/4885ABCC1 1856/4885CYP11B2 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.